SCHEMBL1200522

SCHEMBL1200522

CC12CC3CC(CC(C3)C1(N)N)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
SLC22A2 O15244 2/20 0.43
SLC47A1 Q96FL8 2/20 0.43
SLC22A1 O15245 1/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
STAT6 P42226 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28003800 0.78 LMNA (0.46) LMNASLC22A2SLC47A1SLC22A1GRIN2D
SCHEMBL811709 0.74 GRIN2D (0.36) LMNASLC22A2SLC47A1SLC22A1GRIN2D
SCHEMBL6860339 0.74 LMNA (0.48) LMNASLC22A2SLC47A1SLC22A1GRIN2D
Ammonia Solution, Strong SCHEMBL3787685 0.72 GRIN2D (0.35) LMNASLC22A2SLC47A1SLC22A1GRIN2D
Water SCHEMBL27943536 0.72 GRIN2D (0.35) LMNASLC22A2SLC47A1SLC22A1GRIN2D
Bromide SCHEMBL28280728 0.72 GRIN2D (0.35) LMNASLC22A2SLC47A1SLC22A1GRIN2D
SCHEMBL1930951 0.72 GRIN2D (0.35) LMNASLC22A2SLC47A1SLC22A1GRIN2D
SCHEMBL7258945 0.71 HSD11B1 (0.34) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1229981 0.70 GRIN2D (0.43) LMNASLC22A2SLC47A1SLC22A1GRIN2D
Ammonia Solution, Strong SCHEMBL528152 0.70 GRIN2D (0.33) LMNASLC22A2SLC47A1SLC22A1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420768-B2 Polymerizable higher diamondoid derivatives CHEVRON U.S.A. INC. (US) 2013-04-16 US disclosed
US-8013078-B2 Heterodiamondoids CHEVRON U.S.A. INC. (US) 2011-09-06 US disclosed
US-7981975-B2 Heterodiamondoids CHEVRON U.S.A. INC. (US) 2011-07-19 US disclosed
US-20110112258-A1 Polymerizable Higher Diamondoid Derivatives CHEVRON U.S.A. INC. (US) 2011-05-12 US disclosed
US-7884256-B2 Addition/condensation polymerization CHEVRON U.S.A. INC. (US) 2011-02-08 US disclosed
US-7795468-B2 Functionalized higher diamondoids CHEVRON U.S.A. INC. (US) 2010-09-14 US disclosed
US-20100190985-A1 Heterodiamondoids CHEVRON U.S.A. INC. (US) 2010-07-29 US disclosed
US-20100094012-A1 Heterodiamondoids CHEVRON U.S.A. INC. (US) 2010-04-15 US disclosed
US-7649056-B2 Triamantane diamondoid nucleus CHEVRON U.S.A. INC. (US) 2010-01-19 US disclosed
EP-1997816-A1 Heterodiamondoids Chevron U.S.A. Inc. (US) 2008-12-03 EP disclosed
US-20060183870-A1 Heterodiamondoids CHEVRON U.S.A. INC. 2006-08-17 US disclosed
US-7049374-B2 Heterodiamondoids CHEVRON U.S.A. INC. (US) 2006-05-23 US disclosed
US-20050159634-A1 Polymerizable higher diamondoid derivatives CHEVRON U.S.A. INC. (US) 2005-07-21 US disclosed
US-6858700-B2 Polymerizable higher diamondoid derivatives CHERVON U.S.A. INC. (US) 2005-02-22 US disclosed
US-20040059145-A1 Heterodiamondoids CHEVRON USA INC. 2004-03-25 US disclosed
US-20030199710-A1 Functionalized higher diamondoids CHEVRON U.S.A. INC. 2003-10-23 US disclosed
EP-1351905-A2 POLYMERIZABLE HIGHER DIAMONDOID DERIVATIVES Chevron USA, Inc. (US) 2003-10-15 EP disclosed
US-20020177743-A1 Polymerizable higher diamondoid derivatives CHEVRON U.S.A., INC. 2002-11-28 US disclosed
WO-2002057201-A2 POLYMERIZABLE HIGHER DIAMONDOID DERIVATIVES CHEVRON U.S.A. INC. (US) 2002-07-25 WO disclosed
US-3832332-A FILMS, FIBERS SUN RESEARCH DEVELOPMENT 1974-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199710-A1 Functionalized higher diamondoids DRD3, DRD4, FANCD2 LMNA 192/4885SLC22A2 4525/4885SLC47A1 4647/4885
US-20050159634-A1 Polymerizable higher diamondoid derivatives PCBP1, XRCC5, DCLRE1A LMNA 593/4885SLC22A2 4530/4885SLC47A1 4842/4885
US-20100190985-A1 Heterodiamondoids WEE2, WEE1, NPM1 LMNA 1171/4885SLC22A2 2105/4885SLC47A1 4142/4885
US-20020177743-A1 Polymerizable higher diamondoid derivatives PCBP1, XRCC5, DCLRE1A LMNA 593/4885SLC22A2 4530/4885SLC47A1 4842/4885
US-20040059145-A1 Heterodiamondoids NPM1, NDC1, WEE2 LMNA 924/4885SLC22A2 2402/4885SLC47A1 4422/4885
US-20100094012-A1 Heterodiamondoids WEE2, WEE1, NPM1 LMNA 1171/4885SLC22A2 2105/4885SLC47A1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.